

Pharmacy:	Phone:
Address:	Fax:
City/State/Zip:	Email:

Neurology Referral Form

	Please attach copy of in	surance cards (front and back)					
Last Name:	First Name:	DOB:	Practic	e:			
Address:			Address:				
City:	State: Zip:	Sex: M F	City:		State:		Zip:
Phone:	SSN# Prescriber			ber Name:			
	Insurance Information Prescriber NPI:						
Insurance Plan:	modranoe mromation						
Policy #	Policy # Phone:						
Plan #	Plan #		Fax:		Ema	il·	
Diagnosis and Clinical Information							
Please attach clinical/progress notes, labs, test supporting primary diagnosis							
Diagnosis	- anaon omnou, progress notes, naze, test experime primary	ICD-10 Code		Allergies:			
1.							
2.							
3.			NKDA:				
4.				Height:			
5.				Weight:			
6.	Prescription I	Information		weight.			
Medication	•	rections				07)/	D. CII
	Administer gm/kg per day for days every weeks	rections			'	QTY	Refills
IVIg SCIg	Administer gm/kg per day for days every weeks						
— Adubalm	IV every 4 weeks as follows: 1 mg/kg for infusions 1 and 2; 3 mg/kg	for infusions 3 and 4					
Aduhelm (aducanumab-avwa)	6mg/kg for infusions 5 and 6; 10mg/kg for Infusions 7 and beyond						
Briumvi (ublituximab)	First infusion: 150mg IV infusion Second infusion: 450mg IV infusion at 2 weeks after first infusion Followed by 450mg IV every 24 weeks						
Kisunla (donanemab-azbt)	700 mg administered over approximately 30 minutes every 4 weeks for the first three doses Followed by 1,400mg every 4 weeks thereafter						
Lemtrada (alemtuzumab)	First infusion: 12mg IV infusion for 5 consecutive days Second infusion: 12mg IV infusion for 3 consecutive days 12 months after first infusion						
Leqembi (lecanemab-irmb)	10mg/kg IV every 2 weeks *MRIs at baseline, prior to 5th, 7th and 14th infusions						
Ocrevus (ocrelizumab)	Starting dose: Infuse 300mg IV on day 1 and day 15 Maintenance dose: Infuse 600mg IV once every 6 months						
Radicava (edaravone)	Starting dose: 60mg IV daily for 14 days followed by a 14-day drug-free period Maintenance dose: 60mg IV daily for 10 days out of 14 followed by a 14-day drug-free period						
Rystiggo (rozanolixizumab)	<pre></pre>						
Soliris (eculizumab)	Starting dose: 900mg IV weekly for 4 weeks, followed by 1,200mg IV for the fifth dose 1 week later Maintenance dose: 1,200mg IV every 2 weeks						
Tysabri (natalizumab)	Infuse 300mg IV every 4 weeks						
Ultomiris (ravulizumab)	Under the starting dose: 2,400mg IV followed in 2 weeks by maintenance dose of 3,000mg IV every 8 weeks Under the starting dose: 2,700mg IV followed in 2 weeks by maintenance dose of 3,300mg IV every 8 weeks Under the starting dose: 3,000mg IV followed in 2 weeks by maintenance dose of 3,600mg IV every 8 weeks						
Uplizna (inebilizumab-cdon)	Starting dose: 300mg IV followed by 300mg at 2 weeks Maintenance dose: 300mg IV starting 6 months after first infusion						
Vyepti (eptinezumab-jjmr)	100mg IV every 12 weeks 300mg IV every 12 weeks						
Vyvgart (efgartigimod alfa)	10mg/kg (1,200mg for weight >120kg) IV once weekly for weeks with weeks between cycles						
Vyvgart-Hytrulo (efgartigimod alfa and hyaluronidase-QVFC)	Myasthenia gravis: 1,008mg efgartigimod alfa/11,200 units hyaluronidase once weekly for 4 weeks CIDP: 1,008mg efgartigimod alfa/11,200 units hyaluronidase once weekly (indefinitely)						
Other							

Neurology Referral Form- Continued				
Pre-medication Pre-medication				
NS Hydration	mLs NS IV to be infused prior/post infusion			
Acetaminophen	1-2 tablets PO prior to infusion or post-infusion as directed			
Diphenhydramine	Take 1 tablet PO prior to infusion or as directed 50mg IV prior to infusion or as directed			
Anaphylaxis	Anaphylaxis per pharmacy protocol			
Other				

I authorize Vital Care Infusion Services LLC and its representatives to initiate any insurance prior authorization process that is required for this prescription and for any future refills of the same perciption for the patient listed above that I order. I understand that I can revoke this designation at any time by providing written notice to Vital Care.

Physician Signature: _	
Date.	

PRESCRIBER MUST MANUALLY SIGN. STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED.

The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, you are prohibited from viewing, copying and/or distributing the information contained herein. Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety.

This form is not considered an order or prescription for medical services and/or supplies unless and until it is formally authorized by a healthcare provider in compliance with applicable laws and regulations.

This is not a valid prescription in the state of Arizona.